HUTCHMED (China) Ltd
LSE:HCM
HUTCHMED (China) Ltd
LSE:HCM
Price:
308 GBX
-0.65%
Market Closed
Updated:
May 8, 2024
Section:
Relative Value
The Relative Value of one
HCM
stock under the Base Case scenario is
390.07
GBX.
Compared to the current market price of 308 GBX,
HUTCHMED (China) Ltd
is
Undervalued by 21%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
HCM
Relative Value
Base Case
390.07
GBX
Undervaluation 21%
Valuation Multiples
Multiples Across Competitors
HCM Competitors Multiples
HUTCHMED (China) Ltd Competitors
HUTCHMED (China) Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| HK |
|
HUTCHMED (China) Ltd
LSE:HCM
|
2.7B GBP | 4 | 33.1 | -2 948.9 | -4 266 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
739.2B USD | 20.6 | 120.4 | 59 | 67.1 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.9T DKK | 16.1 | 44.1 | 32.8 | 36 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
357.9B USD | 4.2 | 9.3 | 11.5 | 15 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
330.2B USD | 5.4 | 143.2 | 35.7 | 58.2 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
187.8B GBP | 4.9 | 37.1 | 174.3 | 278 | |
| CH |
|
Novartis AG
SIX:NOVN
|
175.7B CHF | 3.3 | 11 | 8.4 | 12.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
176.4B CHF | 3 | 15.3 | 8.7 | 10.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.8B USD | 2.8 | -507.4 | 12.6 | 20.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
